-
11.发明公开Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant 失效新颖的，生物活性的多肽，它们的制备方法和含有这些多肽的药物组合物
公开(公告)号：EP1449921A3
公开(公告)日：2006-01-11
申请号：EP04075986.2
申请日：1993-01-28
CPC分类号： B65B69/00 , A61K38/21 , A61K38/38 , A61K47/642 , A61K47/643 , C07K14/575 , C07K14/755 , C07K14/76 , C07K14/765 , C07K2319/00 , C07K2319/02 , C07K2319/31 , C07K2319/33 , C12N9/6456 , A61K2300/00
摘要： La présente invention concerne de nouveaux polypeptides biologiquement actifs, leur préparation et des compositions pharmaceutiques les contenant.
-
公开(公告)号：EP1530639A2
公开(公告)日：2005-05-18
申请号：EP03765208.8
申请日：2003-07-23
发明人： SLEEP, Darrell
IPC分类号： C12N15/62 , C12N15/67 , C12N15/81 , C07K14/765 , C07K14/79
CPC分类号： C07K14/765 , C07K14/79 , C07K2319/02 , C12N15/625 , C12N15/81
摘要： The present invention provides a polypeptide comprising (i) a leader sequence, the leader sequence comprising a (a) secretion pre sequence, and (b) the following motif: -X1-X2-X3-X4-X5- where X1 is phenylalanine, tryptophan, or tyrosine, X2 is isoleucine, leucine, valine, alanine or methionine, X3 is leucine, valine, alanine or methionine, X4 is serine or threonine and X5 is isoleucine, valine, alanine or methionine; and (ii) a desired protein heterologous to the leader sequence. A polypeptide of the invention may additionally comprise, as part of the leader sequence, a secretion pro sequence. The invention also provides a polynucleotide comprising a sequence that encodes a polypeptide of the invention and a cell, preferably a yeast cell, comprising said polynucleotide.
-
公开(公告)号：EP1525222A1
公开(公告)日：2005-04-27
申请号：EP03771166.0
申请日：2003-07-28
发明人： BEREZENKO, Stephen , SADLER, Peter John , STEWART, Alan James , BLINDAUER, Claudia , BUNYAN, Kerry, Emma
IPC分类号： C07K14/765
CPC分类号： C07K14/765
摘要： The present invention relates to mutated forms of serum albumin, which display altered metal binding and/or other characteristics with respect to a native albumin from which the mutant has been derived, as well as uses of such mutant albumins in the medical field or in growth of cells in culture.
-
公开(公告)号：EP1463751A2
公开(公告)日：2004-10-06
申请号：EP02799966.3
申请日：2002-12-23
申请人： Human Genome Sciences, Inc. , Delta Biotechnology Limited , Principia Pharmaceutical Corporation
CPC分类号： C07K14/765 , A61K31/155 , A61K31/426 , A61K31/4439 , A61K31/4965 , A61K38/00 , A61K38/04 , A61K38/17 , A61K38/28 , A61K39/21 , C07K7/06 , C07K14/005 , C07K14/435 , C07K14/4713 , C07K14/4723 , C07K14/475 , C07K14/50 , C07K14/505 , C07K14/51 , C07K14/521 , C07K14/525 , C07K14/535 , C07K14/54 , C07K14/5406 , C07K14/55 , C07K14/555 , C07K14/56 , C07K14/565 , C07K14/575 , C07K14/57563 , C07K14/5759 , C07K14/585 , C07K14/59 , C07K14/60 , C07K14/605 , C07K14/61 , C07K14/62 , C07K14/635 , C07K14/65 , C07K14/655 , C07K14/665 , C07K14/705 , C07K14/7151 , C07K14/82 , C07K16/00 , C07K16/241 , C07K16/26 , C07K2317/622 , C07K2317/76 , C07K2319/00 , C07K2319/20 , C07K2319/30 , C07K2319/31 , C12N7/00 , C12N9/0006 , C12N9/0008 , C12N15/62 , C12N2501/335 , C12N2740/16111 , C12N2740/16134 , C12N2740/16171 , C12Y101/01105 , C12Y102/01 , C12Y207/01095
摘要： The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
-
15.发明授权
公开(公告)号：EP0624195B1
公开(公告)日：2004-09-15
申请号：EP93904129.9
申请日：1993-01-28
CPC分类号： B65B69/00 , A61K38/21 , A61K38/38 , A61K47/642 , A61K47/643 , C07K14/575 , C07K14/755 , C07K14/76 , C07K14/765 , C07K2319/00 , C07K2319/02 , C07K2319/31 , C07K2319/33 , C12N9/6456 , A61K2300/00
摘要： Novel biologically active polypeptides, preparation thereof and pharmaceutical compositions containing said polypeptides.
-
公开(公告)号：EP1031578A3
公开(公告)日：2001-01-17
申请号：EP00201960.2
申请日：1996-02-29
发明人： Goodey, Andrew Robert, Delta Biotechnology Limited , Sleep, Darrell, Delta Biotechnology Limited , Van Urk, Hendrik, Delta Biotechnology Limited , Berezenko, Stephen, Delta Biotechnology Limited , Woodrow, John Rodney, Delta Biotechnology Limited , Johnson, Richard Alan, Delta Biotechnology Limited , Wood, Patricia Carol, Delta Biotechnology Limited , Burton, Stephen James, Delta Biotechnology Limited , Quirk, Alan Victor
IPC分类号： C07K14/765
CPC分类号： C07K14/70571 , C07K14/765 , C07K2319/10
摘要： A process is provided for the preparation of albumin which has extremely low levels of or is essentially free of colorants, metal ions, human proteins, host proteins, fragments of albumin, polymers or aggregates of albumin and viruses, and which is essentially non-glycated, relatively high in free thiol and with an intact C-terminus. The process comprises passing albumin (preferably expressed and secreted by transformed yeast) through positive mode cation exchange and then positive mode anion exchange chromatography. Other steps may also be employed, for example ultrafiltration, gel permeation chromatography, affinity chromatography binding the albumin (for example using blue dyes) and affinity chromatography binding contaminants (for example using an aminophenylboronic acid resin). Elution of albumin, with a compound having affinity for albumin, from a material having no specific affinity for albumin is also disclosed, as is removal of ammonium ions with a counter-ion. Albumin of high purity is preferred by the above process.
-
公开(公告)号：EP0764209A1
公开(公告)日：1997-03-26
申请号：EP95921063.0
申请日：1995-06-07
发明人： WOOD, Patricia Carol, Delta Biotechnology Limited , QUIRK, Alan Victor, Delta Biotechnology Limited
CPC分类号： C07K14/765
摘要： Reduction (preferably elimination) of the HSP150 protein in a yeast used to produce desired foreign proteins, especially human albumin, facilitates subsequent purification of the protein.
-
公开(公告)号：EP0749478A1
公开(公告)日：1996-12-27
申请号：EP95909880.0
申请日：1995-03-01
CPC分类号： C07K14/765 , C12N9/60 , C12N15/81
摘要： Albumin, for example human albumin, is expressed and secreted in yeast which has been mutated to lack the yeast aspartyl protease 3 (Yap3p) or its equivalent, thereby reducing the production of a 45kD albumin fragment. A further reduction is achieved by additionally deleting the Kex2p function. Alternatively, a modified albumin is prepared which is not susceptible to Yap3p cleavage, for example human albumin which is R410A, K413Q and K414Q.
-
公开(公告)号：EP0424117B1
公开(公告)日：1996-07-31
申请号：EP90311381.9
申请日：1990-10-17
CPC分类号： C12N9/2428 , C07K14/765 , C12N15/81
-
公开(公告)号：EP0387319B1
公开(公告)日：1996-03-06
申请号：EP89909015.3
申请日：1989-07-14
IPC分类号： C12N15/81
CPC分类号： C07K14/765 , C07K14/39 , C07K2319/02 , C07K2319/036 , C07K2319/50 , C07K2319/90 , C12N15/625 , C12N15/81
摘要： Secretory leader sequences, for use in secreting heterologous polypeptides in yeast, are formed by fusing part of the human serum albumin pre-sequence or part of the Kluyveromyces lactis killer toxin pre-sequence to the Saccharomyces cerevisiae mating factor alpha-1 KEX2 cleavage recognition site. The resulting fusion leader sequences are: (a) H2N-Met-Lys-Trp-Val-Ser-Phe-Ile-Ser-Leu-Leu-Phe-Leu-Phe-Ser-Ser-Ala-Tyr-Ser-Arg-Ser-Leu-Asp-Lys-Arg-COOH or (b) H2N-Met-Asn-Ile-Phe-Tyr-Ile-Phe-Leu-Phe-Leu-Leu-Ser-Phe-Val-Gln-Gly-Ser-Leu-Asp-Lys-Arg-COOH. Conservative variations are also encompassed.
-
-
-
-
-
-
-
-
-
搜索结果
69 条记录 (耗时 0.049 秒)
